Affinity Moiety Targeting Senescent Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively target and eliminate senescent cells, which contribute to tissue aging and tumorigenesis, as they are not well-characterized and recognized by the immune system for removal.
Innovation Solution
A method involving pharmaceutical agents attached to affinity moieties that specifically bind to polypeptides such as HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, and ITGA3, allowing for targeted delivery or elimination of senescent cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional pharmaceutical agents are administered, then general therapeutic effects are achieved, but selective targeting of senescent cells is not possible
Solution Approach 1:
The patent introduces affinity moieties as intermediary components that bridge pharmaceutical agents and senescent cells. These affinity moieties specifically bind to senescent cell surface markers, enabling selective targeting without requiring complex modification of the entire agent structure. The intermediary affinity moiety resolves the contradiction by providing specific binding capability while keeping the pharmaceutical agent component relatively simple.
Solution Approach 2:
The pharmaceutical agent is segmented into distinct functional components: the therapeutic/pharmaceutical component and the targeting component (affinity moiety). This segmentation allows each component to be optimized independently - the pharmaceutical agent for therapeutic efficacy and the affinity moiety for selective binding to senescent cells, thereby achieving high targeting precision without excessive overall complexity.
2Reliability
If senescent cells are eliminated, then tissue aging and tumorigenesis are reduced, but current methods lack the ability to specifically recognize and eliminate these cells
Solution Approach 1:
The patent employs detectable markers or labels associated with senescent cell surface proteins, enabling visual or instrumental detection of these cells. By tagging or labeling senescent cells through their specific surface markers, the system transforms the previously undetectable senescent cells into identifiable targets, resolving the difficulty of detection and enabling reliable elimination.
Solution Approach 2:
Affinity moieties serve as intermediaries that specifically recognize and bind to senescent cell surface markers. This intermediary binding capability transforms the previously unrecognizable senescent cells into specifically identifiable and targetable objects, enabling reliable detection and subsequent elimination through the administered pharmaceutical agents.
3Ease of operation
If affinity moieties are attached to pharmaceutical agents, then selective targeting of senescent cells is achieved, but the complexity of the pharmaceutical composition increases
Solution Approach 1:
The affinity moiety acts as a modular intermediary component that can be attached to various pharmaceutical agents. This modular approach provides selective targeting capability through a standardized interface, avoiding the need to redesign entire pharmaceutical compositions for each targeting application, thereby limiting the increase in overall complexity.
Solution Approach 2:
The affinity moiety serves multiple functions: it provides selective binding to senescent cells, enables detection through associated markers, and facilitates the delivery of various pharmaceutical agents. This multi-functionality consolidates multiple capabilities into a single component, reducing the overall complexity that would otherwise require separate systems for each function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the selective targeting and potential elimination of senescent cells, which could prevent cancer and treat age-related diseases by leveraging the immune system's recognition of these cells.
Implementation Method 1
the affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3
Data Source
AI summary
A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.